Skip to content

Investigator

Pankaj Kapahi

BUCK INSTITUTE FOR RESEARCH ON AGING · funded by NIA

Companies
3

Resolved onto their grants.

Grants
5

Federal awards on file.

Non-dilutive funding
$2.5M

Summed across those awards.

First award
May 1, 2018

Latest Feb 1, 2026.

Companies from this work

Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.

Grant record

Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.

  1. R01

    Role of OXR1 and the retromer in brain aging and Alzheimer's disease and related dementias

    $809k

    Feb 1, 2026NIABUCK INSTITUTE FOR RESEARCH ON AGINGNIH RePORTER · 11214362 (opens the source filing in a new tab)

  2. R01

    The role of diet and aging in photoreceptor homeostasis and visual function decline

    $731k

    Jul 1, 2024NIABUCK INSTITUTE FOR RESEARCH ON AGINGNIH RePORTER · 11125803 (opens the source filing in a new tab)

  3. R01

    The role of diet and aging in photoreceptor homeostasis and visual function decline

    $745k

    Jul 1, 2024NIABUCK INSTITUTE FOR RESEARCH ON AGINGNIH RePORTER · 11365097 (opens the source filing in a new tab)

  4. R13

    Summer Training Course in Experimental Aging

    $101k

    May 1, 2018NIABUCK INSTITUTE FOR RESEARCH ON AGINGNIH RePORTER · 11167372 (opens the source filing in a new tab)

  5. R13

    Summer Training Course in Experimental Aging

    $100k

    May 1, 2018NIABUCK INSTITUTE FOR RESEARCH ON AGINGNIH RePORTER · 11325884 (opens the source filing in a new tab)

This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources